"Analysts look for a 37% EPS increase to $1.23, and for sales to rise 13.7% to $889.2 million" IBD
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
